Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — Q1 FY24 Earnings Presentation
24 slides from Zim Laboratories's earnings presentation, Aug 15, 2023
Slide 1: Regulation 30 filing cover letter to BSE and NSE
Ref No.: ZLL/CS/BSE/NSE Date: 15.08.2023 BSE Limited, National Stock Exchange of India Limited Market Operations Dept. Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai – 400 051 Company Code- 541400 (Symbol - ZIMLAB) D
Slide 2: Q1FY24 Earnings Presentation August 2023
ZIM Laboratories Limited Q1FY24 Earnings Presentation August 2023
Slide 3: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 4: Business, Financials, Corporate
BUSINESS FINANCIALS CORPORATE OVERVIEW INCOME STATEMENT SHAREHOLDING COMMITTED TO CORE STRATEGY FINANCIALS SHARE PRICE MOVEMENT HIGHLIGHTS R&D AT CORE Q1FY24 EARNINGS CALL DETAILS
Slide 5: Business
BUSINESS
Slide 6: Overview
OVERVIEW ZIM develops and supplies differentiated generic Pharmaceutical and Nutraceutical products in Finished Formulations (FF) and Pre- Formulation Intermediates (PFI) in certain key therapeutic categories across RoW markets Our differentiation and value proposition is in our ability to develop a
Slide 7: Core Strategy Initiatives: Q1 FY24
CORE STRATEGY INITIATIVES : Q1 FY24 In line with our Core Strategy – we filed 20 Dossiers of New Innovative Products (NIP) across Pharmerging and RoW markets; this is in addition to 2 NIP product dossiers filed in EU last quarter In addition to the NIP products, we have filed 19 Upgraded Dossiers of
Slide 8: Highlights: Q1FY24
HIGHLIGHTS : Q1FY24 Total Operating Income for Q1FY24 was Rs 674Mn, down 27% YoY (Rs 927Mn, Q1FY23) and down 36% QoQ (Rs 1054Mn in Q4FY23) Exports business 80% as part of Total The Business in this quarter was impacted primarily due to a drop in export of Operating Nutraceutical products to some of
Slide 9: Highlights: Q1FY24
HIGHLIGHTS : Q1FY24 306 Total Exports in Q1FY24 were Rs 539Mn vs Rs 758Mn in Q1FY23; a decrease of 29% due to INR MN received as currency shortage in some RoW markets and shifting of a large PFI business orders to Q2 proceeds from sale of Escrow Shares Finished Formulations Exports – Business grew t
Slide 10: Highlights: Q1FY24
HIGHLIGHTS : Q1FY24 Key Impact on profitability during Q1FY24 has been primarily on account of a drop in Nutraceutical Business on account of currency availability issues and shift of some nutraceutical orders to Q2. Resultant variance in contribution flows through to PAT Change (Negative) / Particu
Slide 11: Operational Updates: Q1FY24
OPERATIONAL UPDATES : Q1FY24 Powering up together- Introducing our new marketing partnership 1 • ZIM's Board has approved an investment with a local partner to strengthen its capabilities for marketing and distributing New Innovative Products (NIP) and Oral Thin Films (OTF) in Australia and New Zeal
Slide 12: Exports
EXPORTS 758 539 452442 306 97 Exports business for Q1FY24 was Rs 539Mn, down 29% from Rs 758Mn in Q1FY23; Nutra business de growth led to overall decrease in Exports REVENUE MIX % : Q1FY23 Pharmaceuticals exports remained stable YoY; growth was hindered REVENUE MIX % : Q1FY24 by some regular PFI ord
Slide 13: Domestic Business and Deemed Exports
DOMESTIC BUSINESS AND DEEMED EXPORTS Domestic Business (Rs Mn) 95 89 For Q1FY24, our Domestic Business was Rs 89Mn vs Rs 95Mn in Q1FY23 23 6 The domestic business includes sale to Central/ State Government, 43 agencies owned by the Government 27 10 Our range of OTF products in India are marketed by
Slide 14: Business Priorities
BUSINESS PRIORITIES Debt Reduction Committed to Expansion Total Borrowing and Gearing for Q1FY24 stands Upgradation of Plant and Equipment : Rs at Rs 593 Mn and 27% respectively 618Mn (Tangible Assets) invested over last 4 years Continuing with upgrading our facilities and obtaining best of plant &
Slide 15: Financial Overview
FINANCIAL OVERVIEW
Slide 16: Income Statement
INCOME STATEMENT Change % Change % Particulars (Rs Mn) Q1FY24 Q1FY23 Q1FY24 Q4FY23 (YoY) (QoQ) Total Operating Income 674 927 (27.3%) 674 1,054 (36.1%) Other Income 11 19 11 7 57.1% (42.1%) Total Income 685 946 685 1,061 (35.5%) (27.6%) EBITDA 59 131 59 161 (63.4%) (55.0%) EBITDA % 8.8% 14.1% - 8.8%
Slide 17: Financials
FINANCIALS Total Operating Income (Rs Mn) 994 1,010 1,054 927 674 De-growth in Total Operating Income was primarily on account of Q1FY23 Q2 Q3 Q4 Q1FY24 lower Nutraceutical exports during the quarter EBITDA (Rs Mn) and as % of Total Operating Income EBITDA and PAT margins de growth was solely attrib
Slide 18: R&D at Core
R&D AT CORE R&D Expense Mix % Focus on using Differentiated Drug Delivery techniques Total R&D Spend as % of Total Operating Income Non – infringing development and manufacturing process using various technology platforms – - Micro - Emulsion Coating Technology (MECT) - Pellet Cold Forming Technolog
Slide 19: Corporate
CORPORATE
Slide 20: Shareholding
SHAREHOLDING Ownership % (On June ‘23) Traded Volume (In K) BSE+NSE The Company had entered into an escrow agreement in 2017, with one of its shareholder wherein the 22,128 shareholder has provided his 22% holding to the extent of 30 Lakhs 4% equity shares (including 25 Lakhs 5% Bonus shares) as sec
Slide 21: Share Price Movement
SHARE PRICE MOVEMENT ZIM (BSE) vs BSE S&P Healthcare Index ZIM vs NIFTY Healthcare Index 111 113 113 106 8,321 7,547 8,160 7,488 90 91 111 87 26789 83 82 91 79 79 79 87 90 83 82 70 69 71 73 25814 79 79 79 61 73 51 70 69 71 106 23,875 61 23,788 23681 51 22,364 21,635 Jun-22 Jun-23 Jan-23 May-22 May-2
Slide 22: Committed to Core Strategy
COMMITTED TO CORE STRATEGY Current Business : Q1FY24 Outlook : FY24 Pharmaceuticals Nutraceuticals Pharmaceuticals; New Innovative Products (NIP) Nutraceuticals Generic Products Generic Products Branded Generics/OTF 10 2 4 PFI FF / OTF PFI FF New Products Dossiers Fillings (Various Stages of filed i
Slide 23: Q1FY24 Earnings Call Details
Q1FY24 EARNINGS CALL DETAILS Date 16th August, 2023 Time 12 Noon IST Dial – In Details Universal Access Numbers +91-22-62801214/ +91-22-71158115 Diamond Pass Click Here 22
Slide 24: Thank You
For further information, please get in touch with: Investor Relations at ir@zimlab.in Sheetal Khanduja sheetal@GoIndiaadvisors.com M:+91 97693 64166 Deepika Sharma deepika@GoIndiaadvisors.com M:+91 8451029510 Priya Sen priya@GoIndiaadvisors.com M : +91 8334841047 THANK YOU